N-(2-{3-[3,5-Bis(trifluoromethyl)phenyl]ureido}ethyl)-glycyrrhetinamide (6b): A Novel Anticancer Glycyrrhetinic Acid Derivative that Targets the Proteasome and Displays Anti-Kinase Activity

Citations Over TimeTop 10% of 2011 papers

Abstract

18-β-Glycyrrhetinic acid (GA; 1) and many of its derivatives are cytotoxic in cancer cells. The current study aims to characterize the anticancer effects of 17 novel 1 derivatives. On the basis of these studies, N-(2-{3-[3,5-bis(trifluoromethyl)phenyl]ureido}ethyl)-glycyrrhetinamide (6b) appeared to be the most potent compound, with IC(50)in vitro growth inhibitory concentrations in single-digit micromolarity in a panel of 8 cancer cell lines. Compound 6b is cytostatic and displays similar efficiency in apoptosis-sensitive versus apoptosis-resistant cancer cell lines through, at least partly, the inhibition of the activity of a cluster of a dozen kinases that are implicated in cancer cell proliferation and in the control of the actin cytoskeleton organization. Compound 6b also inhibits the activity of the 3 proteolytic units of the proteasome. Compound 6b thus represents an interesting hit from which future compounds could be derived to improve chemotherapeutic regimens that aim to combat cancers associated with poor prognoses.

Related Papers

• → Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors(2009)64 cited
• → Probing the Specificity and Activity Profiles of the Proteasome Inhibitors Bortezomib and Delanzomib(2012)51 cited
• → Macrocyclic Proteasome Inhibitors(2011)17 cited
• The Double Effects of Proteasome Inhibitor on Neuron(2006)
• → Status of proteasome inhibitors in the treatment of multiple myeloma(2013)